fludarabine has been researched along with ipi-145 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, JR; O'Brien, SM; Porter, DL | 1 |
| Armand, P; Arnason, J; Brown, JR; Davids, MS; Fisher, DC; Francoeur, K; Hanna, J; Lee, B; McDonough, M; Montegaard, J; Odejide, O; Tyekucheva, S | 1 |
| Armand, P; Arnason, J; Brown, JR; Davids, MS; Fernandes, SM; Fisher, DC; Gadi, D; Griffith, A; Lederer, JA; Lee, B; Lehmberg, TZ; Machado, JH; Martindale, SP; Odejide, O; Rai, V; Thrash, E; Tyekucheva, S; Vartanov, A; Wang, Z | 1 |
1 review(s) available for fludarabine and ipi-145
| Article | Year |
|---|---|
Novel treatments for chronic lymphocytic leukemia and moving forward.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Small Molecule Libraries; Sulfonamides; Vidarabine | 2014 |
2 trial(s) available for fludarabine and ipi-145
| Article | Year |
|---|---|
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Female; Humans; Induction Chemotherapy; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Grading; Neoplasm Staging; Prognosis; Purines; Rituximab; Treatment Outcome; Vidarabine | 2021 |
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Cyclophosphamide; Cytokines; Humans; Inflammation; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Purines; Rituximab; T-Lymphocytes; Vidarabine | 2022 |